Physician profile
James Ham
NPI 1063192375
$1,558.38
in general payments reported to CMS, 2019-2025
17 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $60.88 · 2024: $384 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.54 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $287.07 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $223.44 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $199.40 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $156.32 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $136.41 | 2023-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.58 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $83.37 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $62.95 | 2025 | Rexulti |
| Lundbeck LLC | $57.95 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $51.09 | 2024-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $49.28 | 2024 | |
| Collegium Pharmaceutical, INC. | $37.13 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $34.06 | 2025 | Exxua, Adzenys Xr-Odt |
| Tms Neurohealth Centers INC. | $24.28 | 2025 | Tms Neurohealth Centers INC. |
| Idorsia Pharmaceuticals US INC | $19.46 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $18.83 | 2025 | Azstarys |
| Noven Therapeutics, LLC | $17.76 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.